Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL161240 | 1.00 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL7700994 | 0.97 | CA4 (0.46) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL11903448 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL7635443 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL518280 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL1655126 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL120390 | 0.94 | CA4 (0.52) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL22401093 | 0.94 | CA4 (0.52) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL21054602 | 0.94 | CA4 (0.52) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL20400343 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119581534-A | Ion conductor coated modified lithium iron phosphate and preparation method and application thereof | 湖南裕能新能源电池材料股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-11850259-B2 | Methods of treating viral infections affecting the respiratory tract using topically administered lithium agents | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-12-26 | — | — | US | claimed |
| US-20230085863-A1 | TELOMERE LENGTH MODULATION USING FIBROBLASTS | FIGENE, LLC | 2023-03-23 | — | — | US | claimed |
| EP-4106777-A1 | TELOMERE LENGTH MODULATION USING FIBROBLASTS | Figene, LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220347208-A1 | FORMULATIONS USING LITHIUM TO TREAT GOUT ARTHROPATHY | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-11-03 | — | — | US | claimed |
| EP-4034136-A1 | FORMULATIONS USING LITHIUM TO TREAT GOUT ARTHROPATHY | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-08-03 | — | — | EP | claimed |
| US-20220218607-A1 | STABLE, LOW-VISCOSITY ANTIBODY FORMULATIONS AND USES THEREOF | SANOFI SA (FR) | 2022-07-14 | — | — | US | claimed |
| WO-2022119914-A1 | METHODS OF INHIBITING RNA PROOFREADING AND THERAPEUTIC APPLICATIONS THEREOF | SCHMIER BRAD (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022076375-A1 | METHODS OF TREATING VIRAL INFECTIONS AFFECTING THE RESPIRATORY TRACT USING TOPICALLY ADMINISTERED LITHIUM AGENTS | The United States Government as Represented by the Department of Veterans Affaires (US) | 2022-04-14 | — | — | WO | claimed |
| US-20220105128-A1 | METHODS OF TREATING VIRAL INFECTIONS AFFECTING THE RESPIRATORY TRACT USING TOPICALLY ADMINISTERED LITHIUM AGENTS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-04-07 | — | — | US | claimed |
| EP-2303302-A2 | A FORMULATION AND METHOD FOR RELIEVING OR PREVENTING SYMPTOMS ASSOCIATED WITH URIC ACID CRYSTALS | Truscott, Kent (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2010132038-A2 | A FORMULATION AND METHOD FOR RELIEVING OR PREVENTING SYMPTOMS ASSOCIATED WITH URIC ACID CRYSTALS | TRUSCOTT KENT (US) | 2010-11-18 | — | — | WO | claimed |
| US-20090269425-A1 | Formulation and method for relieving or preventing symptoms associated with uric acid crystals | TRUSCOTT KENT J | 2009-10-29 | — | — | US | claimed |
| US-20060078629-A1 | Nutritional compositions and use thereof | SERFONTEIN WILLEM J | 2006-04-13 | — | — | US | claimed |
| EP-1643865-A1 | NUTRITIONAL COMPOSITIONS AND USE THEREOF | Serfontein, Willem Jacob (ZA) | 2006-04-12 | — | — | EP | claimed |
| WO-2004107881-A1 | NUTRITIONAL COMPOSITIONS AND USE THEREOF | SERFONTEIN, WILLEM, JACOB (ZA) | 2004-12-16 | — | — | WO | claimed |
| EP-0730463-B1 | USE OF LITHIUM COMPOUNDS IN THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE | LEHMANN KARLA (DE) | 2000-02-02 | — | — | EP | claimed |
| EP-0234733-B1 | PHARMACEUTICAL COMPOSITIONS | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1991-11-13 | — | — | EP | claimed |
| US-4810497-A | Pharmaceutical compositions | EFAMOL LIMITED (GB) | 1989-03-07 | — | — | US | claimed |
| EP-0234733-A1 | Pharmaceutical compositions | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1987-09-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060078629-A1 | Nutritional compositions and use thereof | BHMT, BHMT2, CBS | CA4 4306/4885CTSL 2825/4885CPT2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.